Michael M. Lederman

33.8k citations

381 papers · 24.7k indexed · 5 hit papers · h-index 78

Virology top 0.01%
- HIV Research and Treatment 250
Infectious Diseases top 0.05%
- HIV/AIDS Research and Interventions 89
- HIV/AIDS drug development and treatment 87
Emergency Medicine top 0.02%
- HIV-related health complications and treatments 83
Immunology top 0.1%
- Immune Cell Function and Interaction 108
- T-cell and B-cell Immunology 40
Microbiology top 0.2%
Epidemiology
- Cytomegalovirus and herpesvirus research 41
- Pneumocystis jirovecii pneumonia detection and treatment 30

Co-authors: Benigno Rodríguez Scott F. Sieg Alan Landay Nicholas Funderburg Steven G. Deeks Hernán Valdez Jeffrey N. Martin Peter W. Hunt
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: The Journal of Infectious Diseases (55 papers)AIDS (37 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (31 papers)
Partner nations: United States South Africa United Kingdom

In The Last Decade

Michael M. Lederman

375 papers receiving 24.2k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2014 The Journal of Infectious Diseases
2013 Science Translational Medicine
2009 The Journal of Infectious Diseases
2006 Nature Medicine
1996 New England Journal of Medicine

Peers

Countries citing papers authored by Michael M. Lederman

Since Specialization

Citations

This map shows the geographic impact of Michael M. Lederman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael M. Lederman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael M. Lederman more than expected).

Fields of papers citing papers by Michael M. Lederman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael M. Lederman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael M. Lederman. The network helps show where Michael M. Lederman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael M. Lederman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael M. Lederman Line = papers co-authored together Michael M. Lederman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Interleukin-2 is a potent latency reversal agent in people with treated HIV-1 Science Advances ·Michael L. Freeman,Brian Clagett,Konstantin Leskov,Daniela Moïsi,George A. Yendewa,Scott F. Sieg,Gregory M. Laird,Jonathan Karn,Jeffrey M. Jacobson,Benigno Rodríguez,Michael M. Lederman	2025	0
2	Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV Cell Reports Medicine ·Timothy J. Henrich,Ronald J. Bosch,Catherine Godfrey,Hanna Mar,魏淑香,Michael C. Keefer,Carl J. Fichtenbaum,Daniela Moïsi,Brian Clagett,Amanda M. Buck,Amelia N. Deitchman,G. Gortani,Jonathan Z. Li,Daniel R. Kuritzkes,Michael M. Lederman,Priscilla Y. Hsue,Steven G. Deeks,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2024	5
3	Association of Soluble Markers of Inflammation With Peri-coronary Artery Inflammation in People With and Without HIV Infection and Without Cardiovascular Disease Open Forum Infectious Diseases ·Michael L. Freeman,Mian Bazle Hossain,Shana Burrowes,Jean Jeudy,Lu Liu,Daniela Moïsi,Sarah Mitchell,Lennie V Castillo,Robert G. Weiss,Michael M. Lederman,Shashwatee Bagchi	2023	6
4	Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection Nature Communications ·Natarajan Bhaskaran,Elizabeth Schneider,Fady Faddoul,James William Casamento,Robert Asaad,Aarthi Talla,Neil S. Greenspan,Alan D. Levine,David McDonald,Jonathan Karn,Michael M. Lederman,Pushpa Pandiyan	2021	12
5	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy EBioMedicine ·Mina K. Chung,Sadashiva S. Karnik,Eduardo Michaloski Filho,Cornelia C. Bergmann,John Barnard,Michael M. Lederman,John C. Tilton,Feixiong Cheng,Clifford V. Harding,James B. Young,Neil Mehta,Scott J. Cameron,Keith R. McCrae,Alvin H. Schmaier,Jonathan D. Smith,Ankur Kalra,Surafel Gebreselassie,George Thomas,Chien-Nan Lin,Lars G. Svensson	2020	96
6	Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57+ CD4 T Cells in HIV Infection The Journal of Immunology ·Jacinto Martínez-Ródenas,Stephen R. Morris,Soumya Panigrahi,Amie So,E. G. Larionova,Alexey A. Komissarov,Daria M. Potashnikova,Аnna Lebedeva,Souheil‐Antoine Younes,Karem C. Harth,Vikram S. Kashyap,Elena Vasilieva,Leonid Margolis,David A. Zidar,Scott F. Sieg,Carey L. Shive,Nicholas Funderburg,Sara Gianella,Michael M. Lederman,Michael L. Freeman	2020	26
7	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop SHILAP Revista de lepidopterología ·Dana Gabuzda,Beth D. Jamieson,Ronald G. Collman,Michael M. Lederman,Tricia H. Burdo,Steven G. Deeks,Dirk P. Dittmer,Howard S. Fox,Nicholas Funderburg,Savita Pahwa,Ivona Pandrea,Cara C. Wilson,Peter W. Hunt	2020	48
8	HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia PLoS ONE ·Richard J. Wang,Mindy Nguygen,Daniela Moïsi,Emily Chang,Patrick Byanyima,Sylvia Kaswabuli,Emmanuel Musisi,Ingvar Sanyu,论李,F Santarelli,William Worodria,J. Lucian Davis,Kristina Crothers,Jue Lin,Michael M. Lederman,Peter W. Hunt,Laurence Huang	2019	11
9	Relationships Between Renal Parameters and Serum and Urine Markers of Inflammation in Those With and Without HIV Infection AIDS Research and Human Retroviruses ·Юлия Александровна Долгих,Deming Mi,Ziyue Liu,Christie M. Orschell,Michael M. Lederman,Samir K. Gupta	2015	8
10	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial Blood ·Peter W. Hunt,Nancy S. Shulman,Timothy L. Hayes,Viktor Dahl,Ma Somsouk,Nicholas Funderburg,Bridget McLaughlin,Alan Landay,Oluwatoyin Adeyemi,Justin Moser,Brian Clagett,Benigno Rodríguez,Jeffrey N. Martin,Timothy W. Schacker,Barbara L. Shacklett,Sarah Palmer,Michael M. Lederman,Steven G. Deeks	2013	107
11	Residual Immune Dysregulation Syndrome in Treated HIV infection Advances in immunology ·Michael M. Lederman,Nicholas Funderburg,Rafick‐Pierre Sékaly,Nichole R. Klatt,Peter W. Hunt	2013	250
12	Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial The Journal of Infectious Diseases ·Jonathan Z. Li,Zabrina L. Brumme,Chanson J. Brumme,Hongying Wang,John Spritzler,Michael Robertson,Michael M. Lederman,Mary Carrington,Bruce D. Walker,Robert T. Schooley,Daniel R. Kuritzkes	2011	21
13	A Prospective Cohort Study of Periodontal Disease Measures and Cardiovascular Disease Markers in HIV-Infected Adults AIDS Research and Human Retroviruses ·Lance T. Vernon,Denise C. Babineau,Catherine Demko,Michael M. Lederman,Xuelei Wang,Zahra Toossi,Aaron Weinberg,Benigno Rodríguez	2011	17
14	Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir AIDS Research and Human Retroviruses ·Keith W. Crawford,John Spritzler,Robert C. Kalayjian,Teresa L. Parsons,Alan Landay,Richard B. Pollard,Xinbin Hei,Michael M. Lederman,Charles Flexner	2010	29
15	Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2 Proceedings of the National Academy of Sciences ·Nicholas Funderburg,Michael M. Lederman,Zhimin Feng,Michael G. Drage,Julie K. Jadlowsky,Clifford V. Harding,Aaron Weinberg,Scott F. Sieg	2007	302
16	Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248) JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mary Vogler,Hedy Teppler,Rebecca Gelman,Fred Valentine,Michael M. Lederman,Roger J. Pomerantz,Richard B. Pollard,shiho Yamashita,Charles J. Gonzalez,Kathleen Squires,Ian Frank,Donna Mildvan,Kazlauskas, Tadas,,Barbara Schock	2004	15
17	In Vitro Human Memory CD8 T Cell Expansion in Response to Cytomegalovirus Requires CD4⁺T Cell Help The Journal of Infectious Diseases ·Janelle R. Salkowitz,Scott F. Sieg,Clifford V. Harding,Michael M. Lederman	2004	22
18	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection JAIDS Journal of Acquired Immune Deficiency Syndromes ·David W. Haas,Hulin Wu,Haihong Li,Ronald J. Bosch,Michael M. Lederman,Daniel R. Kuritzkes,Alan Landay,Elizabeth Connick,Constance A. Benson,G. Wilkinson,Harold A. Kessler,Richard B. Kim	2003	49
19	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase AIDS ·Michael M. Lederman,Ray A. McKinnis,Dennis Kelleher,Amy Cutrell,John W. Mellors,Mengkun Chen,Elizabeth Cooney,David W. Haas,Richard Haubrich,James Stanford,James Horton,Alan Landay,William Spreen	2000	69
20	In vivo analysis of Fas/FasL interactions in HIV-infected patients. Journal of Clinical Investigation ·Andrew D. Badley,David H. Dockrell,Lifei Zhao,Steve Ziesmer,Alan Landay,Michael M. Lederman,Elizabeth Connick,Harold A. Kessler,Daniel R. Kuritzkes,David H. Lynch,Patrick C. Roche,H Yagita,C. V. Paya	1998	137

About Michael M. Lederman

Michael M. Lederman is a scholar working on Virology, Emergency Medicine and Infectious Diseases, having authored 381 papers that have together received 24.7k indexed citations. Recurring topics across this work include HIV Research and Treatment (250 papers), Immune Cell Function and Interaction (108 papers), HIV/AIDS Research and Interventions (89 papers), HIV/AIDS drug development and treatment (87 papers), HIV-related health complications and treatments (83 papers), Cytomegalovirus and herpesvirus research (41 papers), T-cell and B-cell Immunology (40 papers) and Pneumocystis jirovecii pneumonia detection and treatment (30 papers). The work is most often cited by research in Virology (13.1k citations), Infectious Diseases (9.8k citations) and Emergency Medicine (5.0k citations). Michael M. Lederman has collaborated with scholars based in United States, South Africa and United Kingdom. Frequent co-authors include Benigno Rodríguez, Scott F. Sieg, Alan Landay, Nicholas Funderburg, Steven G. Deeks, Hernán Valdez, Jeffrey N. Martin, Peter W. Hunt, Daniel C. Douek and Robert Asaad. Their work appears in journals such as The Journal of Infectious Diseases, AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes, Clinical Infectious Diseases and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact